Registration for a live webinar on 'Gamma-delta T cells for immunotherapy of cancer' is now open.See webinar details
Diagnosis and treatment of idiopathic pulmonary fibrosis 1
Published on October 6, 2015 27 min
A selection of talks on Clinical Practice
Behavioral medicine: what it is and what it does
- Dr. Gina Touch Mercer
- University of Arizona College of Medicine - Phoenix, USA
The history and foundations of medical research ethics
- Prof. Dr. Christian Lenk
- Ulm University, Germany
Hello. My name is Luca Richeldi. I'm a professor of respiratory medicine at the University Hospital of Southampton in the United Kingdom. And today, I will speak about the diagnosis and treatment of idiopathic pulmonary fibrosis.
So before going into the specifics and the details of pulmonary fibrosis, let me review with you this recent article published in the New England Journal of Medicine. And discussing the topic of fibrosis, which as you see is defined as a common pathway to organ injury and failure. And there are at least three concepts that I would like to underscore with you from this paper. The first one is that the mechanism of fibrosis and the resultant organ failure account for at least one-third of deaths worldwide. And this has not been recognized properly before, and that means that fibrosis together with other cause of disease is a major driver in mortality in every country in the world. The second concept is that fibrosis having adverse effects, basically in all organs, is a very attractive therapeutic target, and even more so because, and it is the third concept I would like to discuss with you, is that contrary to the widely held perception that scar is permanent, we know now from animal models and from preclinical data that there is evidence pointing to the fact that organ fibrosis is highly plastic in nature. That means that the idea of potentially revert fibrosis is something that needs to be considered as an achievable target for any therapeutical trial.